Solaris gains EU approval for NMOSD
The European Commission (EC) has approved the extension of the current marketing authorization of Solaris (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease, making it the first and only drug cleared for this condition in Europe.
NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord.
Marketed by US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN), Solaris was first approved in Europe in 2011 for the treatment of atypical hemolytic uremic syndrome. The drug is also cleared in Europe for paroxysmal nocturnal hemoglobinuria, as well as for certain patients with refractory generalized myasthenia gravis. The drug generated second-quarter 2019 sales of $980.8 million in the second quarter, up 9.2% compared to the prior-year period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze